Moderna extends decline to 20%; biotech index down 1.6%

The significance here is less the single-session drop than the spillover: a 20% move in one large-cap vaccine name dragging the biotech index down 1.6% suggests index-level exposure to a handful of outsized movers, so sentiment can swing on one company's news rather than sector fundamentals. It affects anyone holding broad biotech exposure, where concentration risk shows up as correlated drawdowns. Whether the decline stays isolated to Moderna or spreads across the index in coming sessions is the open question worth watching.